New pill aims to tame dangerous phosphate levels in dialysis patients
NCT ID NCT07548840
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called TS-172 in 30 adults on hemodialysis who have high phosphate levels. Participants take the drug daily for a period, and researchers check if their phosphate levels drop to a target range. The goal is to see if TS-172 can help control phosphate, a common problem in kidney disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TS-172
- What this could lead to
- If successful, TS-172 could offer a new option to help control phosphate levels in dialysis patients, potentially reducing complications.
- What could go wrong
- This is a small, early-phase study with only 30 participants and no placebo group, so results may not be conclusive. Side effects are not yet well understood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERPHOSPHATEMIA PATIENTS ON HEMODIALYSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taisho selected site
RECRUITINGTokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.